
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Moderna, Thermo Fisher announce long-term strategic collaboration for vaccine, therapies

February 25, 2022 | News

Agreement to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies



Moderna, Inc. and Thermo Fisher Scientific Inc. have announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the US of Spikevax, Moderna's COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.

Over the past several years, Thermo Fisher has been partnering with Moderna to support its development pipeline with both clinical research and contract manufacturing services. This included the quick scale-up of aseptic fill-finish services and packaging of its COVID-19 vaccine.

As part of this expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services including lyophilized and liquid filling. In addition, the company will provide inspection, labeling and final packaging services.